Rosen Law Firm reminds Insulet Corporation (NASDAQ: PODD) shareholders that the deadline to seek appointment as lead plaintiff in a pending federal securities class action is Monday, August 31, 2026.

The lawsuit, captioned Hu v. Insulet Corporation, No. 26-cv-013062 (D. Mass.), charges Insulet and certain officers with violations of the Securities Exchange Act of 1934. It alleges defendants concealed systemic manufacturing defects in its Omnipod insulin delivery systems.

Case Allegations and Market Impact

The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. It alleges defendants made materially false and misleading statements about Insulet’s manufacturing controls and product safety. Specifically, the lawsuit contends management misrepresented the ability to produce "medical grade quality at consumer electronic scale" while defective controls persisted at the Acton, Massachusetts facility.

Levi & Korsinsky LLP highlights that shares plummeted from $236 to $146 per share following two Medical Device Corrections (MDCs). Investors who purchased or acquired Insulet securities during the Class Period are eligible to seek compensation through a contingency fee arrangement.

Timeline of Disclosures

The lawsuit details a series of public assurances that preceded two MDCs:

• February 21, 2025: Management claimed high-yield, safe production of Omnipod 5.
• August 7, 2025: Executives described the supply chain as "robust and secure."
• March 12, 2026: First MDC disclosed; stock drops 6.88% to $219.84.
• May 26, 2026: Second MDC disclosed; stock drops 5.07% to $146.01.

The second MDC on May 26, 2026, revealed that the cannula tear problem extended across Omnipod 5, Omnipod Dash, and legacy Omnipod Eros products, affecting approximately 7 million Pods representing 8.5% of 2025 global production. This followed an initial claim that the March 2026 issue affected only 1.5% of pods produced in the last year.

Disclosure Failures Alleged

Insulet’s FY 2024 and FY 2025 annual reports on Form 10-K contained nearly identical quality assurance language. Both filings stated that outside vendors "are audited periodically by our Quality team" and that the team "inspects and tests our products at various steps in the manufacturing cycle." Quarterly filings on Form 10-Q during the Class Period projected that gross margins would "increase compared with 2024 primarily due to improved manufacturing efficiencies."

The action contends that these descriptions concealed specific deficiencies in manufacturing controls at the Acton facility. The complaint charges that:

• Cannula handling procedures were defective, producing pods with small tears in internal tubing that could cause insulin to leak or under-deliver.
• The quality inspection process failed to detect these defects despite claiming multi-step testing.
• Risk factor language described general risks without disclosing specific control failures already producing defective units.
• After the March 2026 recall, management claimed the issue was limited to "specific lots" when the same defect triggered a second, larger recall two months later.

Lead Plaintiff Process and Counsel

The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Insulet securities during the Class Period to seek appointment as lead plaintiff. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate. The lead plaintiff acts on behalf of all other class members in directing the lawsuit and can select a law firm of its choice to litigate.

Rosen Law Firm encourages investors with losses exceeding $100,000 to secure counsel before the deadline. The firm notes it was ranked No. 1 by ISS Securities Class Action Services for number of settlements in 2017 and has recovered billions for investors. Rosen warns that some firms issuing notices may merely refer clients rather than litigate cases directly. The firm highlights that many notifying firms do not actually handle securities class actions but serve as middlemen referring clients to other litigators. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company and was ranked in the top 4 each year since 2013. In 2019 alone, the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Robbins Geller Rudman & Dowd LLP urges investors to contact attorneys Ken Dolitsky or Michael Albert by calling 800/851-7783 or via email at info@rgrdlaw.com . The firm notes it ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025.

Other firms issuing reminders include:

• Levi & Korsinsky LLP: Contact Joseph E. Levi, Esq., at (212) 363-7500 or jlevi@levikorsinsky.com . SueWallSt, powered by Levi & Korsinsky, also reminds institutional holders to evaluate fiduciary obligations and recovery options.
• Bragar Eagel & Squire, P.C.: Contact partners Brandon Walker or Melissa Fortunato at investigations@bespc.com or (212) 355-4648. Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm with offices in New York, South Carolina, and California, urges investors to discuss their legal rights. The firm represents individual and institutional investors in securities, derivative, and commercial litigation.
• Holzer & Holzer, LLC: Contact Corey D. Holzer, Esq., at (888) 508-6832 or cholzer@holzerlaw.com .
• Faruqi & Faruqi, LLP: Contact James (Josh) Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia, has recovered hundreds of millions of dollars for investors since its founding in 1995. The firm also encourages anyone with information regarding Insulet’s conduct, including whistleblowers and former employees, to contact them.
• Schall, Brown & Schwartz LLP: Contact Brian Schall or David Schwartz at 310-301-3335 or david@schallfirm.com . SBS reminds investors that appointment as lead plaintiff is not required to partake in any recovery and notes the class period runs from February 21, 2025 to May 26, 2026.
• The Law Offices of Frank R. Cruz: Contact Frank R. Cruz at 310-914-5007 or fcruz@frankcruzlaw.com . The firm confirms the class period runs from February 21, 2025, to May 26, 2026, with a lead plaintiff deadline of August 31, 2026.

What the Numbers Show

The escalation from an initial 1.5% production impact claim to an 8.5% global output recall underscores deep systemic issues in Insulet’s manufacturing controls. The divergence between internal reporting—29 Serious Adverse Events—and FDA findings—476 Medical Device Reports—suggests significant gaps in oversight. Furthermore, the concentration of insider selling, particularly the combined $5.9 million in sales by three individual defendants while affirming product safety, reinforces market skepticism regarding management credibility during the class period. The cumulative $90 per share decline reflects the erosion of investor confidence as the scope of defects expanded from specific lots to multiple product lines.

Insulet Corporation (NASDAQ: PODD) management will present at the Wells Fargo 21st Annual Healthcare Conference. The event takes place in Boston on Wednesday, September 9, 2026.

The presentation is scheduled for 2:15 pm Eastern Time. Insulet will discuss its Omnipod brand of tubeless insulin pump technology during the session.

Event Details

A live webcast of the presentation will be available. A replay will also be accessible later. Investors can view the content on the Insulet Investor Relations website.

About Insulet

Headquartered in Massachusetts, Insulet focuses on simplifying life for people with diabetes. The company’s Omnipod Insulin Management System offers an alternative to traditional insulin delivery methods. The tubeless disposable Pod provides up to three days of non-stop insulin delivery without needles.

The flagship Omnipod 5 Automated Insulin Delivery System integrates with a continuous glucose monitor. It manages blood sugar with no multiple daily injections or fingersticks. Users can control the device via a compatible smartphone in the U.S. or through the Omnipod 5 Controller.

Insulet also leverages its Pod design for non-insulin subcutaneous drug delivery across other therapeutic areas.